Abstract | BACKGROUND: To evaluate the response, adverse effects and survival of MVP regimen and TVP regimen. METHODS: RESULTS: The overall responses were 34% (11/32) in the MVP arm and 56% (19/34) in the TVP arm. There were 1 complete response, 10 partial responses in the MVP arm and 1 complete response, 18 partial responses in the TVP arm. TVP regimen appeared to have a higher objective response, but no statistically significant difference in the response was observed between two regimens (Chi-square=2.269, P=0.132). Main side effects were hematological toxicities. Grade III+IV hematological toxicities were significantly higher in the patients of arm TVP than arm MVP, especially neutropenia (79% vs 44%, Chi-square=7.458, P=0.006). Median survival time was 12 months vs 8 months, and 1-, 2-, 3-year survival rates were 53% vs 24% (Chi-square=4.943, P=0.026), 17% vs 6%, 6% vs 0, for arm TVP and arm MVP, respectively.. CONCLUSIONS:
|
Authors | Yanping Hu, Ding Yu, Yuhua Fan, Yuhua Ke, Xiaoyu Fu, Yunhua Zhou, Zhihua Xiao, Hui Jiang, Ling Yang |
Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer
(Zhongguo Fei Ai Za Zhi)
Vol. 6
Issue 3
Pg. 195-7
(Jun 20 2003)
ISSN: 1009-3419 [Print] China |
PMID | 21266118
(Publication Type: English Abstract, Journal Article)
|